| Net sales | 43,486.8a | 41,182.5a | 38,260.6a |
| Cost of sales | -11,227a | -10,767a | -10,577.4a |
| Gross profit | 32,259.8a | 30,415.5a | 27,683.3a |
| Research & innovation expenses | -1,354.7a | -1,288.9a | -1,138.6a |
| Advertising and promotion expenses | -14,008.9a | -13,356.6a | -12,059a |
| Selling, general and administrative expenses | -8,208.7a | -7,626.7a | -7,028.8a |
| Operating profit | 8,687.5a | 8,143.3a | 7,456.9a |
| Other income and expenses | -437.7a | -449.9a | -241.5a |
| Operational profit | 8,249.8a | 7,693.4a | 7,215.4a |
| Finance costs on gross debt | -373.4a | -226.7a | -70.4a |
| Finance income on cash and cash equivalents | 148.7a | 162.1a | 69.8a |
| Finance costs, net | -224.7a | -64.6a | -0.6a |
| Other financial income and expenses | -36.7a | -48.8a | -72.3a |
| Sanofi dividends | 444.5a | 420.9a | 468.2a |
| Profit before tax and associates | 8,432.9a | 8,001a | 7,610.6a |
| Income tax | -2,015.1a | -1,810.6a | -1,899.4a |
| Share of profit in associates | -1.3a | 0.2a | 1.4a |
| Net profit | 6,416.5a | 6,190.5a | 5,712.6a |
| Attributable to | — | — | — |
| Owners of the company | 6,408.7a | 6,184a | 5,706.6a |
| Non-controlling interests | 7.8a | 6.5a | 6a |